https://www.avient.com/sites/default/files/2023-08/Avient General Purchase Conditions.pdf
Compliance with Laws and Avient
Supplier Code of Conduct
12.1 Avient is a member of two supply chain
security programs: U.S.
Supplier will
notify Avient if any Goods supplied to Avient are
specifically designed for military use.
12.3 Supplier shall comply with the Avient
Supplier Code of Conduct “Code” which can be
found at:
https://www.avient.com/sites/default/files/202
0-10/supplier-code-of-conduct.pdf .
12.4 Supplier shall comply with all applicable
commercial and public anti-bribery laws
including the US Foreign Corrupt Practices Act of
1977, the UK Bribery Act of 2010 and the OECD
Convention on Combating Bribery of Foreign
Public Officials in International Business, which
prohibit corrupt offers of anything of value,
either directly or indirectly to anyone, including
government officials, to obtain or keep business
or to secure any other improper commercial
advantage.
Termination and suspension
18.1 Avient is entitled to suspend the
performance of its obligations in whole or in part
or terminate the Agreement with immediate
effect, without prejudice to its right to claim
damages and without any compensation to or
indemnification of Supplier (i) in case Supplier
has been declared bankrupt, is in a state of
liquidation, has ceased or suspended whole or
substantial part of its business, is subject of a
court order or preventative legal scheme of
settlement (ii) in case of non-compliance with
clause 12 including but not limited to, the Avient
Supplier Code of Conduct, import, export or
chemical control regulations, anti-bribery laws,
privacy laws or the provisions of safety, health,
environment and security (iii) in case of not
approved changes in accordance with clause 10;
(iv) failure to make timely progress,
nonperformance, or breach by Supplier of the
Agreement; and (v) for convenience by written
notice to the Supplier in which latter case Avient
and Supplier shall negotiate reasonable
termination charges limited to Supplier’s direct
costs of materials and labor incurred to the date
Avient Terms and Conditions of Purchase for Goods and/or Services
of termination.
https://www.avient.com/sites/default/files/2021-01/w-9-clariant-plastics-coatings-usa-llc-july-20201.pdf
Partnerships that conduct a trade or
business in the United States are generally required to pay a withholding
tax under section 1446 on any foreign partners’ share of effectively
connected taxable income from such business.
Therefore, if you are a U.S. person
that is a partner in a partnership conducting a trade or business in the
United States, provide Form W-9 to the partnership to establish your
U.S. status and avoid section 1446 withholding on your share of
partnership income.
In the cases below, the following person must give Form W-9 to the
partnership for purposes of establishing its U.S. status and avoiding
withholding on its allocable share of net income from the partnership
conducting a trade or business in the United States
https://www.avient.com/investors/events-presentations?page=8
PolyOne IR Presentation – Global High Yield & Leveraged Finance Conference – 2/24/2020 to 2/26/2020
https://www.avient.com/investors/events-presentations?page=3
PolyOne IR Presentation – Global High Yield & Leveraged Finance Conference – 2/24/2020 to 2/26/2020
https://www.avient.com/investors/events-presentations?page=5
PolyOne IR Presentation – Global High Yield & Leveraged Finance Conference – 2/24/2020 to 2/26/2020
https://www.avient.com/investors/events-presentations?page=0
PolyOne IR Presentation – Global High Yield & Leveraged Finance Conference – 2/24/2020 to 2/26/2020
https://www.avient.com/investors/events-presentations?page=1
PolyOne IR Presentation – Global High Yield & Leveraged Finance Conference – 2/24/2020 to 2/26/2020
https://www.avient.com/sites/default/files/2023-01/AVNT Dec 2022 Earnings Presentation.pdf
EBITDA Margins
• Focus on organic growth
combined with transformative
and bolt-on acquisitions
• Divested commodity businesses
tied to more cyclical end markets
• Expanded presence in high
growth areas of sustainable
solutions, specialty healthcare
applications, composites and
more resilient end markets
5.4%
11.5%
16.1%
2006 2018 2022PF
$142
$408
$585
2006 2018 2022PF
2006 figures exclude joint venture results
19
RETURNING CASH TO SHAREHOLDERS
Growing Dividend
0.1 0.1
0.2
0.5
0.6
0.7
0.8
0.9
0.9
1.0 1.0 1.0
11 12 13 14 15 16 17 18 19 20 21 22
0.16
0.20
0.26
0.34
0.42
0.50
0.58
0.72
0.79 0.81
0.85
0.95
0.99
11 12 13 14 15 16 17 18 19 20 21 22 23
~$1Bn
REPURCHASED
OVER LAST 11 YEARS
~$550MM
PAID OVER LAST 11 YEARS
Dividends Share Repurchases
Cumulative Buybacks
$B
n
$
p
e
r
sh
ar
e
2022 PRO FORMA
ADJUSTED EPS
Earnings Growth
Expanding Profitability
$0.15
$1.09
$2.08
$2.67
2009 2012 2015 2018 2022PF
T H IR D Q UART ER 2022
RE S U LTS
$110
$119
$0.61
$0.59
Q3 2022 PERFORMANCE
(TOTAL COMPANY CONT.
https://www.avient.com/sites/default/files/2025-01/AVNT Dec 2022 Earnings Presentation Updated.pdf
EBITDA Margins
• Focus on organic growth
combined with transformative
and bolt-on acquisitions
• Divested commodity businesses
tied to more cyclical end markets
• Expanded presence in high
growth areas of sustainable
solutions, specialty healthcare
applications, composites and
more resilient end markets
5.4%
11.5%
16.1%
2006 2018 2022PF
$142
$408
$585
2006 2018 2022PF
2006 figures exclude joint venture results
19
RETURNING CASH TO SHAREHOLDERS
Growing Dividend
0.1 0.1
0.2
0.5
0.6
0.7
0.8
0.9
0.9
1.0 1.0 1.0
11 12 13 14 15 16 17 18 19 20 21 22
0.16
0.20
0.26
0.34
0.42
0.50
0.58
0.72
0.79 0.81
0.85
0.95
0.99
11 12 13 14 15 16 17 18 19 20 21 22 23
~$1Bn
REPURCHASED
OVER LAST 11 YEARS
~$550MM
PAID OVER LAST 11 YEARS
Dividends Share Repurchases
Cumulative Buybacks
$B
n
$
p
e
r
sh
ar
e
2022 PRO FORMA
ADJUSTED EPS
Earnings Growth
Expanding Profitability
$0.15
$1.09
$2.08
$2.67
2009 2012 2015 2018 2022PF
T H IR D Q UART ER 2022
RE S U LTS
$110
$119
$0.61
$0.59
Q3 2022 PERFORMANCE
(TOTAL COMPANY CONT.
https://www.avient.com/sites/default/files/resources/FAQs%2520for%2520PolyOne%2520GHS%2520Requirements%2520Ver%252006%2520April%25202015.pdf
This means that when inhaled, the effects may be indicated from testing conducted by the manufacturer,
but that under other use or exposure conditions, the effect is not associated.